Our research focus

Targeting Strategies in Cancer

We have identified a series of molecules selectively expressed on cancer cells, and in the tumour microenvironment, that can be targeted for cancer therapy. This includes conformationally exposed receptor epitopes, such as found on the Epidermal Growth Factor Receptor (EGFR) and which led to the development of mAb806 and our first-in-human trials of this molecule. Our research findings have provided a new paradigm in antibody-based targeting and therapy of solid tumours. This work has expanded to incorporate structure-function studies of additional novel antibodies we have developed that target cell surface receptors and tumour microenvironment in tumours, as well as investigating mechanisms of resistance to antibody therapeutics, and targeting key molecules involved in sustaining the tumour microenvironment.

Antibody Engineering

We have developed techniques for generation and humanisation of antibodies. Recent molecular engineering, structural and modelling approaches in our laboratory have defined novel Fc:FcRn and Fc:FcγR interactions, which result in improved immune effector function and bioavailability of humanised antibodies. We have also developed strategies to deliver payloads specifically to tumours through conjugation of drugs, toxins and isotopes to recombinant antibodies, peptides and nanoparticles, both in preclinical models and more recently in clinical trials in cancer patients. These studies are showing encouraging results in patients with cancers of the brain, colon and breast, as well as other solid tumours.

Tumour Payload Delivery

The development of recombinant antibodies for cancer therapy has emerged as one of the most promising areas in oncology therapeutics, both as single agents, and for payload delivery. The concept of being able to deliver toxins through antibody-drug conjugates, or radiotherapy by antibody-radioisotope conjugates targeting the payload to sites of disease, are exciting and promising approaches that we are exploring preclinically and clinically with antibodies developed in our laboratory.

Novel Metabolic Tracers

An exciting recent development in the molecular imaging of cancer comes from the identification of critical biochemical pathways responsible for tumour growth and metastasis, and immune targets which can be exploited for therapy, which can be imaged with novel SPECT and positron emission tomography (PET) tracers. Taking the discovery of novel metabolic tracers in the laboratory to clinical trials is a major focus of our molecular imaging / PET research program and is leading to a deeper understanding of tumour biology and therapy response.

Fast facts

An immune protein normally produced within the body, that can recognise and eliminate foreign substances that can cause tissue damage.

Cancer scientists are able to develop and introduce antibodies into the body. They can be designed to recognise and target a specific feature of the tumour to inhibit or stop tumour growth.

Molecular imaging technologies which allow researchers to see whether treatments are effectively targeting a tumour, and how a tumour responds to treatment.

Recent publications

BioMed Central

Perspectives on joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards for [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors

DOI: 10.1186/s40644-022-00512-z

20 December 2022

View abstract
Science Direct

18F-labeling and initial in vivo evaluation of a Hitomi peptide for imaging tissue transglutaminase 2

DOI: 10.1016/j.nucmedbio.2022.11.002

26 November 2022

View abstract

Identification of Potential Biomarkers for Cancer Cachexia and Anti-Fn14 Therapy

DOI: 10.3390/cancers14225533

10 November 2022

View abstract

Our team

Meet our researchers

  • Prof Andrew Scott AM - Head, Tumour Targeting Program | Head, Tumour Targeting Laboratory | Co-Director, Centre for Research Excellence in Brain Cancer | Director, Department Of Molecular Imaging And Therapy, Austin Health | Head, ACRF Centre for Precision Medicine  Publications
  • Prof Hui Gan - Clinical Research Lead | Clinician Scientist | Co-Director, Centre for Research Excellence in Brain Cancer | Director, Cancer Clinical Trials Centre, Austin Health  Publications
  • Zhanqi Liu - Associate Investigator
  • Ingrid Burvenich - Senior Research Scientist  Publications
  • Christian Wichmann - Senior Research Scientist Publications
  • Sagun Parakh - Clinician Scientist | Postdoctoral Research Fellow Publications
  • Eliza Hawkes - Clinician Scientist Publications
  • Laura Osellame - Postdoctoral Research Fellow Publications
  • Zhipeng Cao - Postdoctoral Research Fellow
  • Benjamin Gloria - Senior Production Scientist Publications
  • Angela Rigopoulos - Senior Research Officer Publications
  • Diana Cao - Senior Research Officer
  • Laura Allan - Senior Research Officer
  • Nancy Guo - Senior Research Officer Publications
  • Nhi Huynh - Senior Research Officer
  • Fiona Scott - Program Manager Publications
  • Jodie Palmer - Lymphoma Program Manager
  • Kerryn Westcott - Scientific Project Officer | Student Administrator, School of Medicine LTU Publications

  • Clare Senko - PhD Student
  • Sadia Quazi - PhD Student
  • Siddharth Menon - PhD Student
  • Allison Barraclough - Honorary Clinician
  • Farshad Foroudi - Honorary Clinician Publications
  • Michael Chao - Honorary Clinician
  • Prof Michael McKay - Honorary Clinician Publications
  • Raef Boktor - Honorary Clinician
  • Richard Khor - Honorary Clinician
  • Stephen Chin - Honorary Clinician
  • Sweet Ping Ng - Honorary Clinician
  • Sze-Ting Lee - Honorary Clinician Publications
  • Alexander Mcdonald - Honorary Publications
  • Cameron Johnstone - Honorary
  • Kunthi Pathmaraj - Honorary
  • Uwe Ackermann - Honorary